TY - JOUR
T1 - Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis
AU - Rodríguez-Toscano, Elisa
AU - Martínez, Kenia
AU - Fraguas, David
AU - Janssen, Joost
AU - Pina-Camacho, Laura
AU - Arias, Bárbara
AU - Vieta, Eduard
AU - Mezquida, Gisela
AU - Amoretti, Silvia
AU - Bernardo, Miguel
AU - Castro-Fornieles, Josefina
AU - Cuesta-Zorita, Manuel Jesús
AU - Lobo, Antonio
AU - González-Pinto, Ana
AU - Collado, Iluminada Corripio
AU - Mané, Anna
AU - Arango, Celso
AU - Parellada, Mara
N1 - Funding Information:
David Fraguas has been a consultant and/or has received fees from Bristol-Myers-Squibb, EISAI, Janssen, Lundbeck, and Otsuka. David Fraguas and Laura Pina-Camacho have received grant support from Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness) and from Fundación Alicia Koplowitz. Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Janssen, Lundbeck, Novartis, Otsuka, Richter, Sage, Sanofi-Aventis, and Takeda. A González-Pinto has received grants and served as consultant, advisor or CME speaker for the following entities: Almirall, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Glaxo-Smith-Kline, Janssen-Cilag, Ferrer, Johnson & Johnson, Lundbeck, Merck, Otsuka, Pfizer, Sanofi-Aventis, Servier, Shering-Plough, Solvay, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), the Basque Government, the Stanley Medical Research Institute, and Wyeth.
Funding Information:
Supported by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO), Instituto de Salud Carlos III (PI12/01303, PI13/02112, PI14/00397, FlammPEPS, SAF16-75500-R), co-financed by ERDF Funds from the European Commission, “A way of making 16 Europe”, CIBERSAM. Madrid Regional Government (S2010/BMD-2422 AGES, AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); FP7-HEALTH- F4-2010-241959 (Project PERS), and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916; Project PRISM), Fundación Alicia Koplowitz, Fundación Mutua Madrileña and Fundación Familia Alonso. ERA-NET NEURON (Network of European Funding for Neuroscience Research). EV thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI15/00283, PI17/01249, PI17/00997, PI18/00753) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2017 SGR 1365) and the project SLT006/17/00357, from PERIS 2016–2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014 SGR 1636).
Funding Information:
Supported by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) , Instituto de Salud Carlos III ( PI12/01303 , PI13/02112 , PI14/00397 , FlammPEPS , SAF16-75500-R ), co-financed by ERDF Funds from the European Commission, “A way of making 16 Europe”, CIBERSAM. Madrid Regional Government ( S2010/BMD-2422 AGES , AGES-CM-2 ), European Union Structural Funds , European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); FP7-HEALTH- F4-2010-241959 (Project PERS), and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916 ; Project PRISM), Fundación Alicia Koplowitz, Fundación Mutua Madrileña and Fundación Familia Alonso. ERA-NET NEURON (Network of European Funding for Neuroscience Research). EV thanks the support of the Spanish Ministry of Science, Innovation and Universities ( PI15/00283 , PI17/01249 , PI17/00997 , PI18/00753 ) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2017 SGR 1365) and the project SLT006/17/00357, from PERIS 2016–2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014 SGR 1636).
Publisher Copyright:
© 2021 SEP y SEPB
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Introduction: Core dysfunctions proposed for psychotic disorders include prefrontal cortex (PFC) dopaminergic hypoactivity, executive function (EF) deficits and reduced gray matter in the PFC. The Val variant of COMT Val158Met polymorphism is associated with reduced dopaminergic signaling in the PFC. However, it is unclear how COMT Val158Met modulates PFC gray matter reduction, EF deficits and symptom severity at the time of the first psychotic episode. Methods: The effect of COMT on both EF performance and prefrontal volume (PFC-VOL) was tested in 158 first episode psychosis (FEP) patients and 141 healthy controls (HC) matched for age (range 9–35 years), sex, ethnicity, handedness and COMT Val158Met distribution. EF and PFC-VOL were compared between FEP and HC groups within each polymorphism status (Met/Met versus Val carriers) to assess whether COMT influenced diagnostic differences. Next, correlations between PFC-VOL and EF performance were computed, as well as between both variables and other clinical characteristics of interest (PANSS scores, PAS infancy and premorbid IQ) in the FEP sample. Results: COMT influenced the diagnostic differences mainly in PFC-VOL, but also in EF performance. FEP-Val carriers showed lower EF scores and reduced PFC-VOL compared to the HC group but also poorer EF performance than FEP Met/Met. Poorer EF performance was associated with smaller PFC-VOL, and both were related to increased severity of negative symptoms, poorer premorbid adjustment, and lower estimated premorbid IQ in FEP patients. Conclusions: Our findings suggest that COMT Val158Met polymorphism might contribute to PFC-VOL reductions, executive dysfunctions and symptom severity in FEP patients.
AB - Introduction: Core dysfunctions proposed for psychotic disorders include prefrontal cortex (PFC) dopaminergic hypoactivity, executive function (EF) deficits and reduced gray matter in the PFC. The Val variant of COMT Val158Met polymorphism is associated with reduced dopaminergic signaling in the PFC. However, it is unclear how COMT Val158Met modulates PFC gray matter reduction, EF deficits and symptom severity at the time of the first psychotic episode. Methods: The effect of COMT on both EF performance and prefrontal volume (PFC-VOL) was tested in 158 first episode psychosis (FEP) patients and 141 healthy controls (HC) matched for age (range 9–35 years), sex, ethnicity, handedness and COMT Val158Met distribution. EF and PFC-VOL were compared between FEP and HC groups within each polymorphism status (Met/Met versus Val carriers) to assess whether COMT influenced diagnostic differences. Next, correlations between PFC-VOL and EF performance were computed, as well as between both variables and other clinical characteristics of interest (PANSS scores, PAS infancy and premorbid IQ) in the FEP sample. Results: COMT influenced the diagnostic differences mainly in PFC-VOL, but also in EF performance. FEP-Val carriers showed lower EF scores and reduced PFC-VOL compared to the HC group but also poorer EF performance than FEP Met/Met. Poorer EF performance was associated with smaller PFC-VOL, and both were related to increased severity of negative symptoms, poorer premorbid adjustment, and lower estimated premorbid IQ in FEP patients. Conclusions: Our findings suggest that COMT Val158Met polymorphism might contribute to PFC-VOL reductions, executive dysfunctions and symptom severity in FEP patients.
KW - Executive function
KW - First episode psychosis
KW - Genetics
KW - Prefrontal volume
KW - Schizophrenia and other psychosis
UR - http://www.scopus.com/inward/record.url?scp=85123299645&partnerID=8YFLogxK
U2 - 10.1016/j.rpsm.2021.11.002
DO - 10.1016/j.rpsm.2021.11.002
M3 - Article
AN - SCOPUS:85123299645
SN - 1888-9891
VL - 15
SP - 74
EP - 87
JO - Revista de Psiquiatria y Salud Mental
JF - Revista de Psiquiatria y Salud Mental
IS - 2
ER -